Abstract
Cyclooxygenases (COXs), the enzymes involved in the formation of prostaglandins from polyunsaturated fatty acids such as arachidonic acid, exist in two forms-the constitutive COX-1 that is cytoprotective and responsible for the production of prostaglandins and COX-2 which is induced by cytokines, mitogens and endotoxins in inflammatory cells and responsible for the increased levels of prostaglandins during inflammation. As a result COX-2 has become the natural target for the development of anti-inflammatory and anticancer drugs. While the conventional NSAIDs with gastric side effects inhibit both COX-1 and COX-2, the newly developed drugs for inflammation with no gastric side effects selectively block the COX-2 enzyme. NSAIDs, nonselective non-aspirin NSAIDs and COX-2 selective inhibitors, are being widely used for various arthritis and pain syndromes. Selective inhibitors of COX-2, however, convey a small but definite risk of myocardial infarction and stroke; the extent of which varies depending on the COX-2 specificity. In view of the gastric side effects of conventional NSAIDs and the recent market withdrawal of rofecoxib and valdecoxib due to their adverse cardiovascular side effects there is need to develop alternative anti-inflammatory agents with reduced gastric and cardiovascular problems. The present study reviews various Computer Aided Drug Design (CADD) approaches to develop Cyclooxygenase based anti-inflammatory and anti-cancer drugs.
Keywords: Cyclooxygenase-2, Non-steroidal anti-inflammatory drugs, Docking, homology modeling, 3D-QSAR, CoMFA, CoMSIA, Free Energy Perturbation
Current Pharmaceutical Design
Title: Computer Aided Drug Design Approaches to Develop Cyclooxygenase Based Novel Anti-Inflammatory and Anti-Cancer Drugs
Volume: 13 Issue: 34
Author(s): R. N. Reddy, Ravichandra Mutyala, P. Aparoy, P. Reddanna and M. Rami Reddy
Affiliation:
Keywords: Cyclooxygenase-2, Non-steroidal anti-inflammatory drugs, Docking, homology modeling, 3D-QSAR, CoMFA, CoMSIA, Free Energy Perturbation
Abstract: Cyclooxygenases (COXs), the enzymes involved in the formation of prostaglandins from polyunsaturated fatty acids such as arachidonic acid, exist in two forms-the constitutive COX-1 that is cytoprotective and responsible for the production of prostaglandins and COX-2 which is induced by cytokines, mitogens and endotoxins in inflammatory cells and responsible for the increased levels of prostaglandins during inflammation. As a result COX-2 has become the natural target for the development of anti-inflammatory and anticancer drugs. While the conventional NSAIDs with gastric side effects inhibit both COX-1 and COX-2, the newly developed drugs for inflammation with no gastric side effects selectively block the COX-2 enzyme. NSAIDs, nonselective non-aspirin NSAIDs and COX-2 selective inhibitors, are being widely used for various arthritis and pain syndromes. Selective inhibitors of COX-2, however, convey a small but definite risk of myocardial infarction and stroke; the extent of which varies depending on the COX-2 specificity. In view of the gastric side effects of conventional NSAIDs and the recent market withdrawal of rofecoxib and valdecoxib due to their adverse cardiovascular side effects there is need to develop alternative anti-inflammatory agents with reduced gastric and cardiovascular problems. The present study reviews various Computer Aided Drug Design (CADD) approaches to develop Cyclooxygenase based anti-inflammatory and anti-cancer drugs.
Export Options
About this article
Cite this article as:
Reddy N. R., Mutyala Ravichandra, Aparoy P., Reddanna P. and Reddy Rami M., Computer Aided Drug Design Approaches to Develop Cyclooxygenase Based Novel Anti-Inflammatory and Anti-Cancer Drugs, Current Pharmaceutical Design 2007; 13 (34) . https://dx.doi.org/10.2174/138161207782794275
DOI https://dx.doi.org/10.2174/138161207782794275 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics Analytical Techniques for DNA Methylation – An Overview
Current Pharmaceutical Analysis The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine The Mutator Phenotype in Cancer: Molecular Mechanisms and Targeting Strategies
Current Drug Targets Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development
Current Pharmaceutical Biotechnology Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect
Current Pharmaceutical Biotechnology Subject Index To Volume 4
Current Pharmacogenomics Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology The Design and Characterization of a Novel beta-casein Nano-vehicle Loaded with Platinum Anticancer Drug for Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Tissue-Specific Methylation of Long Interspersed Nucleotide Element-1 of Homo Sapiens (L1Hs) During Human Embryogenesis and Roles in Neural Tube Defects
Current Molecular Medicine New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
Current Clinical Pharmacology Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer
Current Pharmaceutical Design Recent Advances in New Discovered Molecular Targets in Testicular Germ Cell Tumors
Current Medicinal Chemistry